Intellia Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
NTLA$11.17-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the
Condensed Consolidated Statements of Cash Flows (unaudited)
(Amounts in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(114,329) | $(107,436) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,498 | 2,512 |
| Stock-based compensation | 21,840 | 34,176 |
| Accretion of investment discounts | (2,280) | (5,285) |
| Recognition of equity method investment intra-entity profit on sales | - | (20,967) |
| Change in fair value of investments, net | 2,125 | 6,065 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,987) | 29 |
| Prepaid expenses and other current assets | 218 | (8,746) |
| Operating lease right-of-use assets | 7,218 | 4,951 |
| Other assets | (13,826) | 724 |
| Accounts payable | (1,869) | 5,569 |
| Accrued expenses | (14,415) | (22,403) |
| Deferred revenue | (5,095) | (5,368) |
| Operating lease liabilities | (29,028) | (4,483) |
| Net cash used in operating activities | (148,930) | (120,662) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property and equipment | (735) | (2,506) |
| Purchases of marketable securities | (83,209) | (259,558) |
| Sales and maturities of marketable securities | 178,272 | 267,965 |
| Net cash provided by investing activities | 94,328 | 5,901 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Net proceeds from issuance of common stock through at-the-market offerings | - | 58,034 |
| Proceeds from options exercised | - | 1,958 |
| Net cash provided by financing activities | - | 59,992 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | (54,602) | (54,769) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 202,787 | 240,353 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $148,185 | $185,584 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents to condensed consolidated balance sheet: | ||
| Cash and cash equivalents | $126,880 | $171,979 |
| Restricted cash equivalents, included in prepaid expenses and other current assets, and investments and other assets | 21,305 | 13,605 |
| Total cash, cash equivalents and restricted cash equivalents | $148,185 | $185,584 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||
| Purchases of property and equipment unpaid at period end | $82 | $847 |
| Reduction of right-of-use assets from remeasurement of lease liabilities | 61,917 | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.